Medical News Today: Colorectal Cancer News
Latest Health News and Medical News posted throughout the day, every day.
Updated: 22 hours 37 min ago
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
According to the American Cancer Society, the lifetime risk of developing colorectal cancer is around 1 in 20. But according to a recent report from the Centers for Disease Control and Prevention, there are more than 20 million adults in the US who have never had the recommended screening for the disease, putting them at higher risk of dying from a preventable condition.
New research from the US suggests an individual's particular mix of gut microbes may help the development of colorectal cancer tumors by interacting with genes and inflammatory responses.Colorectal cancer happens because healthy cells in the gut start to behave oddly following changes or mutations in their genes.
Activation of beta-catenin, the primary mediator of the ubiquitous Wnt signaling pathway, alters the immune system in lasting and harmful ways, a team of Chicago-based researchers demonstrate in the journal Science Translational Medicine.
Colon cancer screening rates went up by nearly 40% in a Kaiser Permanente study that mailed test kits to patients' homes. The pilot study, funded by the National Institutes of Health (NIH), was part of a program to address disparities among uninsured, low-income and Latino patients. The findings are to be published in the journal BMC Cancer.Lead author Dr.
Eleven of the country's leading gastroenterology (GI) practices have announced the formation of the Digestive Health Physicians Association (DHPA), a trade association comprised of independent gastroenterology physician practices with the aim of promoting and preserving the integrated model of healthcare delivery.
Compared to other diseased cells, malignant tumor cells often exhibit modified surface glycosylation patterns, potentially altering recognition by host immune cells. Natural killer (NK) cells are sentinels of cancer immunosurveillanc system and express multiple receptors that allow for discrimination between healthy and malignant cells.
Mailing free tests to patients' homes boosts colon cancer screening rates in underserved populations
Colon cancer screening rates increased by nearly 40 percent when free stool tests were mailed to patients' homes, according to results of a pilot study published in the journal BMC Cancer.The study, funded by the National Institutes of Health (NIH), included 869 patients who received their health care from community health centers in the Portland, Ore. metropolitan area.
Non-infectious illnesses like cancer and cardiovascular diseases are rising globally, but they are hard to diagnose because of lack of biomarkers, and in countries with poor infrastructure, expensive diagnosis using mammograms and colonoscopy is not available to many.
Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment.
New research published in Nature Communications details the discovery of a potential new drug that selectively kills dormant cancer cells in tumors by inducing mitochondrial dysfunction.The research team, led by Prof.
While new and better treatments have improved the odds of survival for patients diagnosed with late stage colorectal cancer, that progress has been largely confined to non-Hispanic whites and Asians and those under age 65, according to a new study. American Cancer Society researchers led by Helmneh Sineshaw, M.D.
University of Adelaide research has shown for the first time that grape seed can aid the effectiveness of chemotherapy in killing colon cancer cells as well as reducing the chemotherapy's side effects.
Hope for development of drugs to stall the growth of K-Ras cancers, previously deemed impossible to treat
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies to thwart tumor growth.
Obesity is a known risk factor for many cancers including colon cancer, yet the reasons behind the colon cancer link have often remained unclear.
Tests that require patients to collect a single stool sample at home and then send it to a lab for analysis will detect about 79 percent of colorectal cancers, according to a new evidence review published in the Annals of Internal Medicine.
Repeat colonoscopy examined in patients with polyps referred for surgery without biopsy-proven cancer
A new study reports that in the absence of biopsy-proven invasive cancer, a second colonoscopy done at an expert center may be appropriate to reevaluate patients referred for surgical resection. In the study, 71 percent of the lesions referred for surgery were noncancerous polyps (growths in the colon) and were treatable endoscopically.
Previous research has suggested that a diet rich in fiber may reduce the risk of colon inflammation and cancer. But new research suggests that niacin, also known as vitamin B3, may also help protect against these conditions.The research team, including co-author Dr.
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.In a study described in the journal Cancer-Cell, Marikki Laiho, M.D., Ph.D.
Advantage in overall survival, but disadvantage in severe side effectsRegorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an option.